Clinical trials in Senhora Da Hora – page 7

95 clinical trials in Senhora Da Hora, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Senhora Da Hora at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

95 trials in Senhora Da Hora

Open in trial search

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo

Portugal

Participants:18–64 years
Substances:Ofatumumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Insulin Glargine
Sponsor:Novo Nordisk A/S

Contact Research Centre

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:BAY 3283142
Sponsor:Bayer AG

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Batoclimab
Sponsor:Immunovant Sciences GmbH

Contact Research Centre

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Saline
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Novartis Pharma AG

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Avelumab
Sponsor:Bicycletx Limited

Contact Research Centre

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:BAY 2927088
Sponsor:Bayer AG

Contact Research Centre

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Bemarituzumab
Sponsor:Amgen Inc.

Contact Research Centre

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

Registered drug

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

Registered drug

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Senhora Da Hora

What the registry says about research in the country

01 Neurology & Mental Health

Innovative research focusing on Alzheimer's disease and associated conditions, including studies on psychosis treatment and cognitive decline prevention. Multiple trials exploring migraine prevention with novel therapeutic approaches.

Alzheimer's Disease Management
Migraine Prevention
Multiple Sclerosis Treatment

Studies are evaluating both symptomatic relief and disease modification strategies.

02 Oncology

Comprehensive research in breast cancer treatments, particularly focusing on HR+/HER2- variants and innovative combination therapies. Advanced studies in non-small cell lung cancer exploring new treatment paradigms.

Breast Cancer Therapeutics
Lung Cancer Treatment
Head and Neck Cancer

Trials emphasize targeted therapies and immunotherapy approaches.

03 Respiratory Medicine

Groundbreaking research in severe asthma management and chronic rhinosinusitis. Studies evaluating new treatments for COPD with focus on long-term safety and efficacy.

Asthma Management
COPD Treatment
Rhinosinusitis Therapy

Emphasis on innovative inhaler combinations and targeted biological treatments.

Back to Portugal All countries